PCSK9 inhibition is now a validated target for reducing LDL-C and ASCVD
• mAb therapy requires 12-26 injections per year
• Adherence with PCSK9 mAbs is not substantially better than that with statins 2
ORION-1: Diabetes status subgroups
Major progress in ASCVD -but challenges remain
Poor adherence and LDL-C variability are associated with poor outcomes 3 • Approximately 9% of ASCVD risk is attributable to poor adherence 4 • Limitations are most relevant in high risk patients
RNAi harnessing
Viable option to inhibit PCSK9 and lower LDL-C 1
ORION-1: Diabetes status subgroups
Inclisiran: A novel agent to address unmet needs 
Safety data • No concerns

Efficacy data
• All patients responded at 300 mg dose given 2x with significant LDL-C lowering
• Mean LDL-C at 6 months: 53% (absolute reduction 64 mg/dL)
• Maximum LDL-C at 6 months: 81% No unexplained or persistent elevations in any liver parameter considered related to inclisiran No symptomatic/clinically significant elevations of creatinine kinase in any inclisiran-treated group
For the primary efficacy endpoint at 180 days, 300 mg inclisiran given at Day 1 and 90
• Lowered LDL-C by >50% in persons with ASCVD or ASCVD-risk equivalents, regardless of whether they had diabetes or not
• Had no effect on glycemia 
